These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38761652)

  • 1. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
    J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS treatment de-escalation: review and commentary.
    Selmaj K; Hartung HP; Mycko MP; Selmaj I; Cross AH
    J Neurol; 2024 Aug; ():. PubMed ID: 39093335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
    Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
    Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment discontinuation in older people with multiple sclerosis.
    Zhu W; Xia Z
    Curr Opin Neurol; 2024 Jun; 37(3):220-227. PubMed ID: 38567633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
    Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
    Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care.
    Ozen NPA; Dursun EG; Tuncer A; Karabudak R
    Mult Scler Relat Disord; 2024 Apr; 84():105503. PubMed ID: 38422633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.
    Vollmer BL; Wolf AB; Sillau S; Corboy JR; Alvarez E
    Front Neurol; 2021; 12():799138. PubMed ID: 35145470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
    Wu X; Wang L; Shen L; Tang K
    EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.
    Gross RH; Corboy J
    Curr Neurol Neurosci Rep; 2024 Sep; 24(9):341-353. PubMed ID: 38995483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 13. Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
    Piedrabuena MA; Correale J; Fiol M; Marrodan M; Rojas JI; Alonso M; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Cohen L; Alonso R; Silva B; Luetic G; Deri N; Burgos M; Liwacki S; Piedrabuena R; Tkachuk V; Barboza A; Martinez A; Balbuena ME; Pinheiro AA; Nofal P; Lopez PA; Tavolini D; Leguizamon F; Hryb JP; Tizio S; Recchia L; Reich E; Contentti EC; Marcilla MP; Pagani F; Cabrera LM; Curbelo MC; Mainella C; Liguori NF; Coppola M; Pettinicchi JP; Carra A; Jose G; Nadur D; Bestoso S; Pestchanker C; Vazquez GD; Martinez CM; Ysrraelit MC
    J Neurol Sci; 2024 Jun; 461():123052. PubMed ID: 38797140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
    Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
    Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying therapy prescription patterns in people with multiple sclerosis by age.
    Zhang Y; Salter A; Jin S; Culpepper WJ; Cutter GR; Wallin M; Stuve O
    Ther Adv Neurol Disord; 2021; 14():17562864211006499. PubMed ID: 33868459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.